Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Adipose-derived resistin and gut-derived resistin-like molecule–β selectively impair insulin action on glucose production
Michael W. Rajala, … , Philipp E. Scherer, Luciano Rossetti
Michael W. Rajala, … , Philipp E. Scherer, Luciano Rossetti
Published January 15, 2003
Citation Information: J Clin Invest. 2003;111(2):225-230. https://doi.org/10.1172/JCI16521.
View: Text | PDF
Article Metabolism

Adipose-derived resistin and gut-derived resistin-like molecule–β selectively impair insulin action on glucose production

  • Text
  • PDF
Abstract

The adipose-derived hormone resistin is postulated to link obesity to insulin resistance and diabetes. Here, the infusion of either resistin or the resistin-like molecule–β (RELMβ) rapidly induced severe hepatic but not peripheral insulin resistance. In the presence of physiologic hyperinsulinemia, the infusion of purified recombinant resistin, increasing circulating resistin levels by approximately twofold to 15-fold, inhibited glucose metabolism such that lower rates of glucose infusion were required to maintain the plasma glucose concentration at basal levels. The effects of resistin and RELMβ on in vivo insulin action were completely accounted for by a marked increase in the rate of glucose production. These results support the notion that a novel family of fat- and gut-derived circulating proteins modulates hepatic insulin action.

Authors

Michael W. Rajala, Silvana Obici, Philipp E. Scherer, Luciano Rossetti

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
(a) Schematic representation of the pancreatic and insulin clamp procedu...
(a) Schematic representation of the pancreatic and insulin clamp procedure. During the first 2 hours, the rate of insulin infusion was adjusted periodically in order to maintain the plasma glucose concentration at basal levels (insulin as needed). During the last 30 minutes of this 2-hour period, the rate of insulin infusion was stable in all rats and these individualized rates were continued throughout the study. At the completion of the pancreatic clamp (at t = 120 minutes), an additional infusion of insulin (3 mU/kg/min) was administered to similarly raise the plasma insulin levels in all groups, and a variable infusion of a 25% glucose solution was started and periodically adjusted (glucose as needed) to maintain the plasma glucose concentration at approximately 7 mM for the rest of the study. (b) Time course of plasma resistin during pancreatic and insulin clamps. Quantitation of Western blots was achieved by comparison to a standard curve of increasing amounts of recombinant mouse resistin (left panels). Bottom panels show representative Western blot analysis of plasma from rats infused with mouse resistin (mU/kg/min) at the rate of 5 μg/h (low) and 25 μg/h (high). A single band was recognized at about 10 kDa. Comparison with standards allowed us to estimate the serum concentration of mouse resistin during the infusion studies. Basal levels of plasma resistin in C57BL/6 mice averaged 81 ± 23 ng/ml using this semiquantitative Western analysis. (c) Detection of plasma RELMβ in rat plasma. One-half ml or 1 ml of serum was used in immunoprecipitation (IP) experiments followed by Western blots (left). The antibody detected recombinant (Rec.) RELMβ but not recombinant resistin (right).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts